MISTMilestone Pharmaceuticals Inc
$1.15
$0.11
(10.58%)
Closed $1.15
$0.03
(2.61%)
After Hours
EarningsAug 12
Mkt Cap$129.48M
Vol1.74M
After Plunging 20.2% in 4 Weeks, Here's Why the Trend Might Reverse for Milestone Pharmaceuticals (MIST)
Milestone Pharmaceuticals (MIST) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Zacks
Alpha Cognition Announces Election of Dr. Robert Wills as Chairman of the Board
Alpha Cognition Inc. (Nasdaq: ACOG) (Alpha Cognition, or the Company), a biopharmaceutical company focused on developing novel therapies for debilitating neurodegenerative disorders, today announced changes to its Board of Directors. Robert Wills has been elected Chairman of the Board, succeeding...
Business Wire
Milestone Pharmaceuticals (MIST) Reports Q1 Loss, Lags Revenue Estimates
Milestone Pharmaceuticals (MIST) delivered earnings and revenue surprises of -433.33% and -99.68%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Milestone Pharmaceuticals (MIST) Projected to Post Earnings on Wednesday
Milestone Pharmaceuticals (NASDAQ:MIST) will be releasing its Q1 2026 earnings before the market opens on Wednesday, May 13. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-13-milestone-pharmaceuticals-inc-stock...
MarketBeat
Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Short Interest Update
Milestone Pharmaceuticals Inc. (NASDAQ:MIST - Get Free Report) saw a large increase in short interest in the month of April. As of April 15th, there was short interest totaling 10,325,577 shares, an...
MarketBeat
Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Receives Average Rating of "Moderate Buy" from Analysts
Shares of Milestone Pharmaceuticals Inc. (NASDAQ:MIST - Get Free Report) have been assigned an average rating of "Moderate Buy" from the six brokerages that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has...
MarketBeat
Insider Selling: Milestone Pharmaceuticals (NASDAQ:MIST) CEO Sells 36,500 Shares of Stock
Milestone Pharmaceuticals Inc. (NASDAQ:MIST - Get Free Report) CEO Joseph Oliveto sold 36,500 shares of the firm's stock in a transaction dated Thursday, April 16th. The stock was sold at an average...
MarketBeat
Joseph Oliveto Sells 36,500 Shares of Milestone Pharmaceuticals (NASDAQ:MIST) Stock
Milestone Pharmaceuticals Inc. (NASDAQ:MIST - Get Free Report) CEO Joseph Oliveto sold 36,500 shares of the firm's stock in a transaction dated Thursday, April 16th. The shares were sold at an average price of $2.26, for a total value of $82,490.00. Following the completion of the sale, the chief...
MarketBeat
Milestone Pharmaceuticals (NASDAQ:MIST) Upgraded to Strong-Buy at Raymond James Financial
Raymond James Financial raised Milestone Pharmaceuticals to a "strong-buy" rating in a research note on Thursday...
MarketBeat
Milestone Pharmaceuticals (NASDAQ:MIST) Lowered to "Sell" Rating by Wall Street Zen
Wall Street Zen downgraded shares of Milestone Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Saturday...
MarketBeat
<
1
2
>
Advertisement|Remove ads.
CRWV19
9
COIN1
3
LMND2
6Advertisement|Remove ads.